open access

Vol 52, No 2 (2018)
Original research articles
Submitted: 2017-03-01
Get Citation

Monocyte/high-density lipoprotein ratio predicts the mortality in ischemic stroke patients

Asli Bolayir, Seyda Figul Gokce, Burhanettin Cigdem, Hasan Ata Bolayir, Ozlem Kayim Yildiz, Ertugrul Bolayir, Suat Ahmet Topaktas
DOI: 10.1016/j.pjnns.2017.08.011
·
Neurol Neurochir Pol 2018;52(2):150-155.

open access

Vol 52, No 2 (2018)
Original research articles
Submitted: 2017-03-01

Abstract

Objective

The inflammatory process is a very important stage in the development and prognosis of acute ischemic stroke (AIS). The monocyte to high-density lipoprotein (HDL) ratio (MHR) is accepted as a novel marker for demonstrating inflammation. However, the role of MHR as a predictor of mortality in patients with AIS remains unclear.

Methods

We retrospectively enrolled 466 patients who were referred to our clinic within the first 24hours of symptom presentation and who were diagnosed with AIS between January 2008 and June 2016. Four hundred and eight controls of similar age and gender were also included. The patient group was classified into two groups according to 30-day mortality. The groups were compared in terms of monocyte counts, HDL, and MHR values.

Results

The patient group had significantly higher monocyte counts and lower HDL levels; therefore, this group had higher values of MHR compared to controls. Additionally, the monocyte count and MHR value were higher, and the HDL level was lower in non-surviving patients (p<0.001). The MHR value was also observed as a significant independent variable of 30-day mortality in patients with AIS (p<0.001). The optimum cut-off value of MHR in predicting the 30-day mortality for patients with AIS was 17.52 (95% CI 0.95–0.98).

Conclusion

Our study demonstrated that a high MHR value is an independent predictor of 30-day mortality in patients with AIS.

Abstract

Objective

The inflammatory process is a very important stage in the development and prognosis of acute ischemic stroke (AIS). The monocyte to high-density lipoprotein (HDL) ratio (MHR) is accepted as a novel marker for demonstrating inflammation. However, the role of MHR as a predictor of mortality in patients with AIS remains unclear.

Methods

We retrospectively enrolled 466 patients who were referred to our clinic within the first 24hours of symptom presentation and who were diagnosed with AIS between January 2008 and June 2016. Four hundred and eight controls of similar age and gender were also included. The patient group was classified into two groups according to 30-day mortality. The groups were compared in terms of monocyte counts, HDL, and MHR values.

Results

The patient group had significantly higher monocyte counts and lower HDL levels; therefore, this group had higher values of MHR compared to controls. Additionally, the monocyte count and MHR value were higher, and the HDL level was lower in non-surviving patients (p<0.001). The MHR value was also observed as a significant independent variable of 30-day mortality in patients with AIS (p<0.001). The optimum cut-off value of MHR in predicting the 30-day mortality for patients with AIS was 17.52 (95% CI 0.95–0.98).

Conclusion

Our study demonstrated that a high MHR value is an independent predictor of 30-day mortality in patients with AIS.

Get Citation

Keywords

Monoycte, High density lipoprotein, Monocyte to high density lipoprotein ratio, Acute ischemic stroke, Mortality

About this article
Title

Monocyte/high-density lipoprotein ratio predicts the mortality in ischemic stroke patients

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 52, No 2 (2018)

Pages

150-155

DOI

10.1016/j.pjnns.2017.08.011

Bibliographic record

Neurol Neurochir Pol 2018;52(2):150-155.

Keywords

Monoycte
High density lipoprotein
Monocyte to high density lipoprotein ratio
Acute ischemic stroke
Mortality

Authors

Asli Bolayir
Seyda Figul Gokce
Burhanettin Cigdem
Hasan Ata Bolayir
Ozlem Kayim Yildiz
Ertugrul Bolayir
Suat Ahmet Topaktas

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl